RCL
83
-2
URI
60
-6
CTSH
60
-3
C
62
4
PEG
62
4
ETR
65
2
EXPD
43
-4
BMY
55
-8
REGN
38
-2
AXP
67
-2
MRO
50
4
DIS
85
3
ESS
62
-3
BEN
50
9
LLY
28
-8
ECL
55
-2
GLW
45
-3
CRM
60
-7
MMM
35
-5
SIG
44
-3
RCL
83
-2
URI
60
-6
CTSH
60
-3
C
62
4
PEG
62
4
ETR
65
2
EXPD
43
-4
BMY
55
-8
REGN
38
-2
AXP
67
-2
MRO
50
4
DIS
85
3
ESS
62
-3
BEN
50
9
LLY
28
-8
ECL
55
-2
GLW
45
-3
CRM
60
-7
MMM
35
-5
SIG
44
-3
Financhill
Back

Protagonist Therapeutics Quote, Financials, Valuation and Earnings

Trump wins! Dow to 75,000? Details here

See the explosive "Document 20" details here.
Sell
26

PTGX
Protagonist Therapeutics

Last Price:
41.14
Seasonality Move:
12.96%

7 Day Trial

ALL ACCESS PASS

$ 7

Trump's "Document 20" Revealed: Smart Americans Could Get Rich During His 2nd Term

See if stocks could soar as much as 1,000% if history repeats itself.

Protagonist Therapeutics Price Quote

$41.14
+0.03 (+0.24%)
(Updated: November 16, 2024 at 5:34 AM ET)

Protagonist Therapeutics Key Stats

Sell
26
Protagonist Therapeutics (PTGX) is a Sell
Day range:
$39.41 - $41.84
52-week range:
$15.58 - $48.89
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
7.83
P/B ratio:
4.6%
Volume:
1.1M
Avg. volume:
544.4K
1-year change:
152.36%
Market cap:
$2.4B
Revenue:
$60M
EPS:
$2.66

How Much Does Protagonist Therapeutics Make?

Is Protagonist Therapeutics Growing As A Company?

Data Unavailable

Protagonist Therapeutics Stock Price Performance

What Is Protagonist Therapeutics 52-Week High & Low?

Protagonist Therapeutics Price To Free Cash Flow

Is It Risky To Buy Protagonist Therapeutics?

Is Protagonist Therapeutics Cash Flow Positive?

  • What Is PTGX Cash Flow From Operations?
    Cash flow from operations (TTM) is $230.3M
  • What Is Protagonist Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $22.3M
  • What Is Protagonist Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$352M

Protagonist Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    PTGX return on invested capital is 37.59%
  • What Is Protagonist Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 33.69%
  • What Is PTGX Return On Equity?
    ROE is a measure of profitability and is 37.59%

Protagonist Therapeutics Earnings Date & Stock Price

Protagonist Therapeutics Competitors

Protagonist Therapeutics Dividend Yield

Protagonist Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -1.89%
Revenue: 0% 157.93%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 54.38
Upside from Last Price: 32.27%

Major Shareholders

  • How many PTGX shares are owned by institutional investors?
    109.5M PTGX shares are owned by institutional investors
  • How many PTGX shares are owned by insiders?
    1.1M PTGX shares are owned by insiders